The global rabies immunoglobulin market is anticipated to grow at a CAGR of 6.1% during the forecast period. As a zoonotic disease, it requires close cross-sectoral coordination at the national, regional, and global levels. The rising government initiatives in the market are expected to surge the market growth during the forecast period. Rabies is included in WHO’s new 2021-2030 road map. The 2030 NTD Roadmap is a guiding document for the global response to NTDs and includes regional, progressive targets for rabies elimination. For instance, in 2021, WHO, Food and Agriculture Organization, and World Organization for Animal Health, have prioritized rabies under a one-health approach and launched the ‘United Against Rabies Forum’ (UAR), a multi-stakeholder platform. Moreover, UAR initiates investments in rabies control and coordinates the global rabies elimination efforts to achieve zero human deaths from dog-mediated rabies by 2030. Thus, progress in rabies elimination indicates one-health operationalization and strengthened human and animal health systems.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/rabies-immunoglobulin-market
Furthermore, in 2019, Gavi included human rabies vaccines in its vaccine investment strategy 2021-2025 which will support scaling up rabies PEP in Gavi-eligible countries. Its rollout has been disrupted due to the COVID-19 pandemic, the WHO will continue to advise on best strategies and practices for its rollout to countries requesting rabies vaccine. On the path towards rabies elimination, countries can request WHO validation of achieving zero human deaths from dog-mediated rabies; seek OIE endorsement of their dog rabies control programs and self-declared freedom from dog rabies. Additionally, Mexico was the first country to have been validated by WHO in 2019 for eliminating human deaths from dog-mediated rabies.
Over and above that, the companies are launching new vaccines to fight rabies which is expected to drive the market growth during the forecast period. For instance, in April 2022, Cadila Pharmaceuticals announced that it has developed a novel three-dose vaccine against rabies. The three-dose vaccine, named ‘ThRabis’, is a recombinant Nanoparticle-based G protein vaccine that is prepared using Virus-like Particle technology. The new vaccine would prove to be a game-changer due to all the existing rabies vaccines require five injections, spread over 28 days for eliminating the threat.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Type
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- including Bharat Serums and Vaccines Ltd. (BSV), CSL Behring, Grifols SA, Guangdong Shuanglin Bio-Pharmacy Co, Ltd., and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Rabies Immunoglobulin Market Report Segment
By Type
- Human Rabies Immune Globulin (HRIG)
- Equine Rabies Immunoglobulin (ERIG)
A full report of Rabies Immunoglobulin Market is available at: https://www.omrglobal.com/industry-reports/rabies-immunoglobulin-market
Rabies Immunoglobulin Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Bharat Serums and Vaccines Ltd. (BSV)
- CSL Behring
- Grifols SA
- Guangdong Shuanglin Bio-Pharmacy Co, Ltd.
- Haffkine Bio-Pharmaceutical Corp. LTD.
- Kamada Ltd.
- Lanzhou Institute Of Biological Products Co., Ltd.
- Premium Serums and Vaccines Pvt.Ltd. (PSVPL)
- Sanofi SA
- Shanghai RAAS Blood Products Co., Ltd.
- Shanghai Serum Bio-technology Co., LTD.
- Shenzhen Weiguang Biological Products Co., Ltd.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
